Signalife awarded new U.S. patent for method to monitor heartbeats

Apr 23 2008

Signalife, Inc. has announced that the United States Patent and Trademark Office has awarded the Company a new and important patent entitled "System For, And Method Of, Monitoring Heartbeats Of A Patient". The patent, which covers 37 claims, will enhance the Company's ability to develop new proprietary products.

Patent attorneys from Fulwider & Patton supervised and executed the patent application along with Chief Technology Officer Budimir S. Drakulic -- the inventor of the patented technology. The new patent is owned by Signalife, Inc. In conjunction with the Patent Office's granting of the patent, the Company will now evaluate whether or not it will file a continuation or continuation-in-part application for the purpose of pursuing additional claim coverage in the technology that may have occurred since the time of the original application.

Budimir S. Drakulic called the patent-issuance-development a "major milestone in the continued proliferation and protection of the Company's core technologies and products." Dr. Drakulic continued to say that issued patents together with significant patent portfolio already submitted to the United States Patent Office and two Frost & Sullivan technology awards represent major achievements for a young medical device company.

The Company currently has several additional patents pending before the United States Patent and Trademark Office covering a wide array of cardiac technologies and products. Dr. Drakulic stated that he is "confident the Company will continue to be successful in obtaining approvals for pending patents of its technologies and products."

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.